NCT00536575 - Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

August 31, 2010

Conditions

Multiple Myeloma

Interventions

DRUG

Bortezomib

"Dose Level 1: Bortezomib 1.3mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 2: Bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 3: Bortezomib 1.6mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle."

DRUG

Sorafenib

"Dose Levels 1 and 2: 200 mg by mouth twice daily~Dose Level 3: 400 mg by mouth twice daily"

Trial Locations (2)

20817

Center for Cancer and Blood Disorders, Bethesda

37023

Tennessee Oncology, PLLC, Nashville